Navigation Links
Dendreon Reports First Quarter 2008 Financial Results
Date:5/8/2008

SEATTLE, May 8 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2008. Revenue for the first quarter of 2008 was $31,000 compared to $80,000 for the quarter ended March 31, 2007.

Dendreon's total operating expenses for the three months ended March 31, 2008 were $19.2 million compared to $32.0 million for the same period in 2007. The significant reduction primarily relates to a decrease of $6.5 million associated with purchases of commercial scale quantities of the antigen used in connection with Dendreon's lead investigational product, Provenge(R) (sipuleucel-T) as well as reduced expenses associated with the IMPACT clinical trial which completed enrollment in October of 2007. The net loss for the quarter ended March 31, 2008 was $19.5 million, or $0.23 per share compared to a net loss for the same quarter of 2007 of $30.9 million, or $0.38 per share, which includes $0.08 per share associated with commercial antigen purchases. Cash, cash equivalents, short-term, and long-term investments at March 31, 2008 totaled $99.5 million compared to $120.6 million at December 31, 2007. Subsequent to March 31, 2008, the Company received approximately $46 million of net proceeds from the registered direct offering that closed on April 8, 2008.

"We had a very productive first quarter, highlighted by our amended Special Protocol Assessment (SPA) for our ongoing Phase 3 clinical study that accelerates our timeline for final results by a year. At Dendreon, our primary focus remains on providing the FDA with the additional clinical data that it needs to support the approval of PROVENGE so that we may offer this promising therapy to the many men with prostate cancer who currently have few appealing treatment options," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We remain in line with our previous financial and operational guidance for 2008, and as a result of our recent financing, we expect to have sufficient resources to carry us through the final analysis of our Phase 3 IMPACT study."

Recent Events:

-- The FDA agreed to amend the IMPACT (IMmunotherapy for Prostate

AdenoCarcinoma Treatment) SPA, accelerating the expected timeline for

final results from the study by approximately one year while

maintaining comparable power to the previous SPA. In addition, the FDA

reconfirmed that either a positive interim or final analysis of

survival would support licensure and enable Dendreon to amend the

Company's biologics license application for PROVENGE.

-- Completed a registered direct stock offering resulting in the receipt

of net proceeds of approximately $46 million. With this cash infusion,

the Company has adequate resources to complete the IMPACT trial and

finance operations through the final analysis of that trial.

-- Presented clinical data from a Phase 1 trial of Neuvenge(TM)

(lapuleucel-T) demonstrating that the Active Cellular Immunotherapy,

which is based on the same Antigen Delivery Cassette(TM) technology as

PROVENGE, may not only have potential clinical benefit in breast

cancer, but also in ovarian and colorectal cancers. These data were

presented in April at the American Association for Cancer Research

annual meeting.

-- In lieu of Dendreon's regularly scheduled quarterly conference call,

the Company will present at several upcoming investor conferences that

will be webcast, two of which are later this month and include:

- Bank of America Health Care Conference on May 13, 2008

- The Rodman & Renshaw 5th Annual Global Healthcare Conference on

May 19, 2008

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended March 31,

2008 2007

Revenue $31 $80

Operating expenses:

Research and development 13,478 24,962

General and administrative 5,675 7,075

Total operating expenses 19,153 32,037

Loss from operations (19,122) (31,957)

Interest income 1,137 1,392

Interest expense (1,531) (293)

Net loss $(19,516) $(30,858)

Basic and diluted net loss per share $(0.23) $(0.38)

Shares used in computation of basic and

diluted net loss per share 83,313 81,577

March 31, December 31,

2008 2007

Balance Sheet Data:

Cash and cash equivalents $63,214 $75,721

Short-term investments 23,552 27,115

Long-term investments 12,775 17,739

Total assets 138,174 161,662

Convertible senior subordinated notes 85,250 85,250

Total stockholders' equity 22,625 40,377


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Announces Closing of Registered Direct Offering
3. Dendreon Announces $47 Million Registered Direct Offering
4. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
5. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
6. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
7. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
8. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
9. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
10. Dendreon Reports Third Quarter 2007 Financial Results
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 30, 2016 , ... Doctors in Italy say mesothelioma ... longer than patients with lower levels. Surviving Mesothelioma has just posted an article on ... cancer centers in Genoa and La Spezia, Italy tested the blood serum, tumors, and ...
(Date:5/27/2016)... ... ... NeuMedics Inc. is pleased to announce that CEO Iain Duncan has been ... 2016. The session begins at 1:10 PM and Iain will present the proof of ... a topical agent and a treatment for ophthalmic complications of diabetes. , Mr. Duncan ...
(Date:5/27/2016)... ... May 27, 2016 , ... Doctors in Italy, Japan, the UK and ... BRCA-1 associated protein (BAP1) gene and its link to malignant mesothelioma. Surviving Mesothelioma has ... read the full article now. , The studies analyzed for the new report ...
(Date:5/26/2016)... 26, 2016  Agriculture nutrients are in the news ... is running their nitrate removal system on ... and coastal regions nationwide are painting the ... widespread issue. NECi Superior Enzymes, a biotechnology ... developed a new, easy to use device that fits ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):